title: DIABETIC MACULAR EDEMA.
abstract: Diabetic macular edema (DME) remains the most common cause of vision loss among diabetic patients. New understanding of the underlying pathophysiology has interest in the potential benefits of the specific pharmacologic therapy, such as treatment with intraocular steroids, anti-vascular endothelial growth factor (VEGF), and protein kinase C-beta (PKCβ) inhibition. At the last time, laser photocoagulation, according to the guidelines of the Early Treatment of Diabetic Retinopathy Study (ETDRS), continues to be primary standard care treatment in most communities. Optical coherence tomography (OCT) is very useful in monitoring macular edema progression and response to treatment.
authors.forename: Ovidiu
authors.initials: O
authors.lastname: Musat
authors.forename: Corina
authors.initials: C
authors.lastname: Cernat
authors.forename: Mahdi
authors.initials: M
authors.lastname: Labib
authors.forename: Andreea
authors.initials: A
authors.lastname: Gheorghe
authors.forename: Oana
authors.initials: O
authors.lastname: Toma
authors.forename: Madalina
authors.initials: M
authors.lastname: Zamfir
authors.forename: Ana Maria
authors.initials: AM
authors.lastname: Boureanu
mesh_terms: D003930:Diabetic Retinopathy / Q000150:complications* / Q000175:diagnosis / Q000628:therapy*; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D056965:Injections, Intraocular; D017075:Laser Coagulation / Q000379:methods; D008269:Macular Edema / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy*; D064546:Protein Kinase C beta / Q000037:antagonists & inhibitors*; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D005938:Glucocorticoids; D042461:Vascular Endothelial Growth Factor A; D064546:Protein Kinase C beta